Life Sciences Archives - Page 11 of 17 - EverGlade

Life Sciences

Rapid Response Test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness

Leave a Comment / All Posts, BARDA, Life Sciences / By

In a continued effort to bolster national preparedness against emerging biological threats, the Biomedical Advanced Research and Development Authority (BARDA) has released the Phase 2 issue of the “Biothreat Diagnostic Rapid Response” Solicitation (RPP-25-06-DxR2) on May 29, 2025, under its Rapid Response Partnership Vehicle (RRPV). BARDA is seeking to address pressing gaps in diagnostic test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness Read More »

Conveyor belt with blue capsules medicine

ASPR RFI: Public Health Industrial Base Capabilities and Capacities: Essential Medicines

Leave a Comment / Life Sciences / By

ASPR Industrial Base Management and Supply Chain Request for Information (RFI) Understanding the RFI The Public Health Industrial Base Capabilities and Capacities: Essential Medicines RFI is seeking detailed input from domestic manufacturers and industry stakeholders to better understand the current capabilities and constraints in producing a list of 28 designated essential medicines. The scope includes

ASPR RFI: Public Health Industrial Base Capabilities and Capacities: Essential Medicines Read More »

Close-up of Medical Ampoule Production Line at Modern Modern Pharmaceutical Factory. Glass Ampoules are being Filled. Medication Manufacturing Process.

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation

Leave a Comment / All Posts, DTRA, Life Sciences / By

Reimagining the Future of Vaccines: DTRA’s RAVEN RFI The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO), has announced a new Request for Information (RFI) under the initiative titled Reimagining Available Vaccines and Envisioning Novelty (RAVEN). This RFI reflects DTRA’s responsibility to prepare the U.S. warfighter for current and emerging

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation Read More »

The White House Initiatives

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety

Leave a Comment / All Posts, ARPA-H, BARDA, Life Sciences / By

Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety Read More »

Chemical Threat Readiness

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes

Leave a Comment / DTRA, Life Sciences / By

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army Contracting Command has issued Solicitation RPP-25-04 seeking Enhanced White Papers for a groundbreaking prototype: the Assay Expansion for Chemical Diagnostic

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes Read More »

immunoassay IEID Lab Solicitation

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats

Leave a Comment / All Posts, BARDA, Life Sciences / By

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats Read More »

PROSPR program

Proactive Solutions for Prolonging Resilience Opportunity Announcement

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

The Foci of PROSPR ARPA-H-SOL-25-125, PROSPR The PROSPR solicitation outlines a comprehensive, multi-year program structured around the development, validation, and deployment of novel health technologies. The program is divided into three primary technical areas (TAs), each addressing a critical component of healthspan extension: TA1 focuses on developing a PROSPR Intrinsic Capacity (IC) score that quantifies

Proactive Solutions for Prolonging Resilience Opportunity Announcement Read More »

organophosphorus nerve agents

Project UPREG

Leave a Comment / All Posts, DTRA, Life Sciences / By

Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs). These highly toxic compounds pose a

Project UPREG Read More »

BARDA merge with ARPA-H

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures

Leave a Comment / All Posts, BARDA, Life Sciences / By

The U.S. Department of Health and Human Services (HHS) is undergoing one of the most significant structural transformations in its history. This realignment affects not only public health preparedness and biomedical innovation but also the broader operational framework, including funding mechanisms, programmatic leadership, and cross-agency coordination structures that supports millions of Americans across health care,

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures Read More »

ARPA-H_Mission Office Innovative Solutions Openings (ISO)

ARPA-H Mission Office Innovative Solutions Openings (ISOs)

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

Overview The Advanced Research Projects Agency for Health (ARPA-H) is dedicated to accelerating transformative health solutions by tackling some of the most pressing challenges in biomedical and healthcare innovation. As part of this mission, ARPA-H has launched Mission Office Innovative Solutions Openings (ISOs) that promote the development of health technologies that lie outside of the

ARPA-H Mission Office Innovative Solutions Openings (ISOs) Read More »

NIH resume issuing grants

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants

Leave a Comment / All Posts, Life Sciences / By

Overview In a major development for the biomedical research community, the National Institutes of Health (NIH) has officially acknowledged that its recent funding freeze was unlawful and has announced the resumption of grant distributions. This decision follows weeks of controversy and legal challenges, during which research institutions, universities, and lawmakers criticized the abrupt halt in

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants Read More »

ARPA-H_RAPID rare disease diagnostics

RAPID Solicitation

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

RAPID_SOL_25_119_FINAL Overview The Advanced Research Projects Agency for Health (ARPA-H) recently announced the newly approved program for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID). The RAPID program aims to significantly improve outcomes for people with rare diseases by reducing diagnostic delays by ≥50%, decreasing misdiagnosis rates, and expanding access to diagnostics. Beyond benefitting the treatment experience of

RAPID Solicitation Read More »

Scroll to Top